R-Tech Ueno Ltd., of Tokyo, started a phase I clinical trial for RTU-1096, which is a vascular adhesion protein-1 (VAP-1) inhibitor with anti-inflammatory and immunomodulatory effects. Assuming safety and tolerability are confirmed with a single dose, the company will further examine its safety, tolerability, and pharmacokinetics with repeated doses.